Category: Thoratec Corp.
Shares of Thoratec rise after the heart pump maker beats Wall Street's forecast with its 1st-quarter results, but arch-rival HeartWare slides after just meeting The Street's bottom line.
ConvaTec names interim chief executive Paul Moraviec as its permanent CEO.
ConvaTec, which is rumored to be exploring a sale, said yesterday that it made its interim CEO, former EMEA president Paul Moraviec, to be its new permanent CEO.
Luxembourg-based ConvaTec, which is owned by private equity firms Avista Capital Partners and Nordic Capital, tapped Moraviec to lead its business in Europe, the Middle East and Africa in 2009.
Results from Thoratec's Roadmap study of its HeartMate II implantable heart pump in less-sick heart failure patients shows significant benefit over optimal medical therapy alone.
Higher-than-expected stroke rates reported in a pair of studies of HeartWare's implantable heart pump this week spook investors, pushing HTWR share prices down more than 8%.
The FDA approves an expansion of the clinical trial for Thoratec's next-generation implantable heart pump, the HeartMate III device.
Thoratec reports higher-than-forecast earnings for the 4th quarter and 2014, on an extra selling week and higher utilization rates for its implantable heart pumps, and says it will narrow its focus to the ventricular assist device market.
Thoratec (NSDQ:THOR) yesterday reported higher-than-forecast earnings for the 4th quarter and 2014, crediting an extra selling week and better utilization rates for its implantable heart pumps.
Thoratec completes enrollment in a European clinical trial for its HeartMate III left ventricular assist device.